BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-131@pharmaconomics
DTSTAMP:20260707T005706Z
DTSTART;VALUE=DATE:20261031
DTEND;VALUE=DATE:20261101
SUMMARY:IBRX Phase 2 — N-803 (IL-15 Superagonist) (estimated date)
DESCRIPTION:Phase 2 trial results for N-803 (IL-15 Superagonist) in Long COVID are due ~ Oct 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT07108036\n\nTrack it: https://www.pharmaconomics.com/e/131
URL:https://www.pharmaconomics.com/e/131
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IBRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR